Abstract
In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n=143) and 0, 1, 2, 12 months (group 2; n=141) was performed in months 3, 7 and 12. In addition, the antibody response was compared one month after the third and one and six months after the last vaccination. Seroprotection rates (anti-HBS>10 IU/l) and antibody titres, given as geometric means (GMTs), were higher in group 1 at month 12 as well as one month after completion of three immunizations. More vaccinees of group 2, however, showed seroprotection at month 3 with higher GMTs. In addition, GMTs in group 2 were higher both one month and six months after the last vaccine dose. Determination of parallel corrected correlation factors demonstrated that age was the most important single factor, followed by body weight and sex. However, no more than 3 % of the variation in the GMT can be explained by the influence of age. Due to decreased compliance with the four-dose schedule with a drop-out rate of approximately 10 % of the vaccinees, the total percentage of initial vaccinees who in the end developed protective antibody levels was higher in the 0, 1, 6 months schedule. Thus, it can be concluded that subjects likely to comply will benefit from the 0, 1, 2, 12 months schedule as more rapid protection is obtained and the higher antibody levels after the booster vaccination at month 12 provide longer protection. However, vaccinees whose compliance might be questionable over a period of 12 months, should be selected for the vaccination 0, 1, 6 months schedule as compliance is at a higher level over this period and advantage can be taken of the booster effect of the third dose given in month 6.
Similar content being viewed by others
References
Deinhardt F: Immunization against hepatitis B. Lancet 1988, i: 875–876.
Jilg W, Deinhardt F: Hepatitis-B-Impfung heute. Münchner Medizinische Wochenschrift 1988, 130: 361–362.
Jilg W, Schmidt M, Deinhardt F: Impfversagen nach Hepatitis-B-Impfung. Deutsche Medizinische Wochenschrift 1990, 115: 1545–1548.
Filion LG, Saginur R, Szczerbak N: Humoral and cellular immune responses by normal individuals to hepatitis B surface antigen vaccination. Clinics of Experimental Immunology 1988, 71: 405–409.
Courouce-Pauty AM, Naret C, Ciancionnoni C, Adhemar JP, Soulier JP: Prevention of viral hepatitis B in haemodialysis units by means of anti-HBs immunoglobulins. In: Fondation Merieux: Transplantation and clinical immunology. Volume IX. Excerpta Medica, Amsterdam, 1978, p. 77.
Dennhöfer L: Hepatitis-B Schutzimpfung. Zum Problem der ungenügenden anti-HBs-Bildung. Deutsche Medizinische Wochenschrift 1990, 115: 1560–1565.
Hollinger FB: Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. American Journal of Medicine 1989, 87, Supplement 3A: 36–40.
Hollinger FB, Adam E, Heilberg D, Melnick JL: Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE (ed): Viral hepatitis. Franklin Institute Press, Philadelphia, 1982, p. 451–466.
Stephenne J: Recombinant versus plasma-derived hepatitis-B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine 1988, 6: 299–303.
Zajac BA, West DJ, McAleer WJ, Scolnick EM: Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. Journal of Infection 1986, 13, Supplement A: 39–45.
Andre FE: Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. American Journal of Medicine 1989, 87, Supplement 3A: 14–20.
Andre FE: Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990, 8, Supplement: 574–578.
Troisi CL, Hollinger FB: Hepatitis B vaccines. In: Popper H, Schaffner F (ed): Progress in liver diseases. Volume 9. Saunders, Orlando, 1989.
Jilg W, Schmidt M, Deinhardt F: Four-year experience with a recombinant hepatitis B vaccine. Infection 1989, 17: 70–76.
Krämer A, Sommer D, Hahn EG, Riecken O: German experimental hepatitis B vaccine. Influence of variation of dosage schedule, sex and age differences on immunogenicity in health care workers. Klinische Wochenschrift 1986, 64: 688–694.
Shaw FE, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, Roehm RR, Talley WS, Hadler SC: The effect of anatomic injection site, age, and smoking on the immune response to hepatitis B vaccination. Vaccine 1989, 7: 425–430.
Horowitz MM, Ershler WB, McKinney WP, Battiola RJ: Duration of immunity after hepatitis B vaccination. Efficacy of low-dose booster vaccine. Annals of Internal Medicine, 1988, 108: 185–189.
Corrao G, Calleri M, Zotti M, Barral C, Russo R, Garella D, Ruggenini AM: Immune response to anti-HBV vaccination. Study of conditioning factors. European Journal of Epidemiology 1988, 4: 492–496.
Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon MS: Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. Journal of the American Medical Association 1985, 254: 3187–3189.
Kammler E, Klingler W: Hepatitis-B-Schutzimpfung. Münchner Medizinische Wochenschrift 1989, 131: 337–340.
Novicki MJ, Tong MJ, Bohmann RE: Alterations in the immune response of nonresponders to the hepatitis B vaccine. Journal of Infectious Diseases 1985, 152: 1245–1248.
Hess G, Rossol S, Voth R, Cheatham-Speth, Clemens R, Meyer zum Büschenfelde KH: Active immunization of homosexual men using a recombinant hepatitis B vaccine. Journal of Medical Virology 1989, 29: 229–231.
Carne CA, Weller IVD, Waite J, Briggs M, Pearce F, Adler MW, Tedder RS: Impaired responsiveness of homosexual men with HIV-antibodies to plasma derived hepatitis B vaccine. British Medical Journal 1987, 294: 866–868.
Köhler H, Dumann H, Meuer S: Hepatitis-B-Impfung bei Dialysepatienten. Deutsche Medizinische Wochenschrift 1990, 115: 264–269.
Bruguera M, Cremades M, Rodicio JL, Alcantar JM, Oliver A, Del Rio G, Esteban-Mur R: Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. American Journal of Medicine 1989, 87, Supplement 3A: 30–32.
Krämer A, Herth D, von Keyserlingk, Ludwig WD, Hampl H, Sommer D, Hahn EG, Riecken E: Non-responsiveness to hepatitis B vaccination: revaccination and immunogenetic typing. Klinische Wochenschrift 1988, 66: 670–674.
Chriske HW, Bock HL, Clemens R: Immunantwort auf Nachimpfungen mit einer rekombinierten Hepatitis B-Vakzine bei Low-and Non-Respondern. Arbeitsmedizin Sozialmedizin Präventivmedizin 1990, 25: 421–422.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hess, G., Hingst, V., Cseke, J. et al. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur. J. Clin. Microbiol. Infect. Dis. 11, 334–340 (1992). https://doi.org/10.1007/BF01962073
Issue Date:
DOI: https://doi.org/10.1007/BF01962073